McDonald suggests one likely target: Albuferon, an interferon drug for hepatitis C now in phase 2 trials that belongs to Human Genome Sciences (nasdaq: HGSI - news - people ).
At the Citigroup ( C) Global Consumer Conference, CFO Jon Moeller unveiled some major adjustments to the Bob McDonald Purpose-driven growth plan namely a halt to expansion until the company gets a grip.